Logo image of SKIN

BEAUTY HEALTH CO/THE (SKIN) Stock Fundamental Analysis

NASDAQ:SKIN - Nasdaq - US88331L1089 - Common Stock - Currency: USD

1.72  -0.01 (-0.58%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SKIN. SKIN was compared to 35 industry peers in the Personal Care Products industry. While SKIN seems to be doing ok healthwise, there are quite some concerns on its profitability. SKIN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SKIN had negative earnings in the past year.
SKIN had a positive operating cash flow in the past year.
SKIN had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: SKIN reported negative operating cash flow in multiple years.
SKIN Yearly Net Income VS EBIT VS OCF VS FCFSKIN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -5.72%, SKIN is not doing good in the industry: 71.43% of the companies in the same industry are doing better.
The Return On Equity of SKIN (-83.62%) is worse than 74.29% of its industry peers.
Industry RankSector Rank
ROA -5.72%
ROE -83.62%
ROIC N/A
ROA(3y)-3.53%
ROA(5y)-10.89%
ROE(3y)-66.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SKIN Yearly ROA, ROE, ROICSKIN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

With a Gross Margin value of 62.52%, SKIN perfoms like the industry average, outperforming 48.57% of the companies in the same industry.
SKIN's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SKIN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.45%
GM growth 5YN/A
SKIN Yearly Profit, Operating, Gross MarginsSKIN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

4

2. Health

2.1 Basic Checks

SKIN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SKIN has been increased compared to 1 year ago.
Compared to 1 year ago, SKIN has a worse debt to assets ratio.
SKIN Yearly Shares OutstandingSKIN Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 50M 100M 150M
SKIN Yearly Total Debt VS Total AssetsSKIN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

SKIN has an Altman-Z score of 0.12. This is a bad value and indicates that SKIN is not financially healthy and even has some risk of bankruptcy.
SKIN has a Altman-Z score of 0.12. This is in the lower half of the industry: SKIN underperforms 77.14% of its industry peers.
SKIN has a debt to FCF ratio of 18.53. This is a negative value and a sign of low solvency as SKIN would need 18.53 years to pay back of all of its debts.
SKIN has a Debt to FCF ratio (18.53) which is comparable to the rest of the industry.
SKIN has a Debt/Equity ratio of 12.01. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of SKIN (12.01) is worse than 85.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 12.01
Debt/FCF 18.53
Altman-Z 0.12
ROIC/WACCN/A
WACC5.97%
SKIN Yearly LT Debt VS Equity VS FCFSKIN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 7.47 indicates that SKIN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 7.47, SKIN belongs to the top of the industry, outperforming 97.14% of the companies in the same industry.
SKIN has a Quick Ratio of 6.43. This indicates that SKIN is financially healthy and has no problem in meeting its short term obligations.
SKIN's Quick ratio of 6.43 is amongst the best of the industry. SKIN outperforms 97.14% of its industry peers.
Industry RankSector Rank
Current Ratio 7.47
Quick Ratio 6.43
SKIN Yearly Current Assets VS Current LiabilitesSKIN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for SKIN have decreased strongly by -231.05% in the last year.
SKIN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -17.97%.
SKIN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.72% yearly.
EPS 1Y (TTM)-231.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
Revenue 1Y (TTM)-17.97%
Revenue growth 3Y8.73%
Revenue growth 5YN/A
Sales Q2Q%-14.5%

3.2 Future

Based on estimates for the next years, SKIN will show a very negative growth in Earnings Per Share. The EPS will decrease by -15.44% on average per year.
The Revenue is expected to grow by 13.35% on average over the next years. This is quite good.
EPS Next Y-52.43%
EPS Next 2Y-7.36%
EPS Next 3Y-15.44%
EPS Next 5YN/A
Revenue Next Year-11.81%
Revenue Next 2Y-3.29%
Revenue Next 3Y-0.5%
Revenue Next 5Y13.35%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SKIN Yearly Revenue VS EstimatesSKIN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M 400M 500M
SKIN Yearly EPS VS EstimatesSKIN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

SKIN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SKIN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SKIN Price Earnings VS Forward Price EarningsSKIN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of SKIN indicates a rather cheap valuation: SKIN is cheaper than 94.29% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 7.26
EV/EBITDA N/A
SKIN Per share dataSKIN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

A cheap valuation may be justified as SKIN's earnings are expected to decrease with -15.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.36%
EPS Next 3Y-15.44%

More info and screens

0

5. Dividend

5.1 Amount

SKIN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEAUTY HEALTH CO/THE

NASDAQ:SKIN (5/16/2025, 11:06:23 AM)

1.72

-0.01 (-0.58%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners86.75%
Inst Owner Change-0.14%
Ins Owners8.64%
Ins Owner Change19.21%
Market Cap216.70M
Analysts48.57
Price Target1.61 (-6.4%)
Short Float %7.11%
Short Ratio8.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.46%
Min EPS beat(2)27.04%
Max EPS beat(2)37.88%
EPS beat(4)4
Avg EPS beat(4)46.92%
Min EPS beat(4)20.82%
Max EPS beat(4)101.96%
EPS beat(8)8
Avg EPS beat(8)63.51%
EPS beat(12)11
Avg EPS beat(12)133.67%
EPS beat(16)13
Avg EPS beat(16)27.18%
Revenue beat(2)2
Avg Revenue beat(2)6.36%
Min Revenue beat(2)5.78%
Max Revenue beat(2)6.94%
Revenue beat(4)3
Avg Revenue beat(4)1.85%
Min Revenue beat(4)-9.83%
Max Revenue beat(4)6.94%
Revenue beat(8)4
Avg Revenue beat(8)-0.47%
Revenue beat(12)7
Avg Revenue beat(12)1.79%
Revenue beat(16)11
Avg Revenue beat(16)5.46%
PT rev (1m)0%
PT rev (3m)-8.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-38.08%
EPS NY rev (1m)6.84%
EPS NY rev (3m)-0.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-17.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-13.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.67
P/FCF 7.26
P/OCF 6.02
P/B 4.7
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.25
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)0.24
FCFY13.77%
OCF(TTM)0.29
OCFY16.61%
SpS2.56
BVpS0.37
TBVpS-0.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.72%
ROE -83.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.52%
FCFM 9.26%
ROA(3y)-3.53%
ROA(5y)-10.89%
ROE(3y)-66.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.45%
GM growth 5YN/A
F-Score6
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 12.01
Debt/FCF 18.53
Debt/EBITDA N/A
Cap/Depr 22.94%
Cap/Sales 1.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.47
Quick Ratio 6.43
Altman-Z 0.12
F-Score6
WACC5.97%
ROIC/WACCN/A
Cap/Depr(3y)42.98%
Cap/Depr(5y)45.87%
Cap/Sales(3y)3.35%
Cap/Sales(5y)3.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-231.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
EPS Next Y-52.43%
EPS Next 2Y-7.36%
EPS Next 3Y-15.44%
EPS Next 5YN/A
Revenue 1Y (TTM)-17.97%
Revenue growth 3Y8.73%
Revenue growth 5YN/A
Sales Q2Q%-14.5%
Revenue Next Year-11.81%
Revenue Next 2Y-3.29%
Revenue Next 3Y-0.5%
Revenue Next 5Y13.35%
EBIT growth 1Y52.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year117.36%
EBIT Next 3Y32.72%
EBIT Next 5Y34.66%
FCF growth 1Y129.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y144.35%
OCF growth 3YN/A
OCF growth 5YN/A